Micro-cap biotech Intelligent Bio Solutions Inc. (INBS) has been on quite a ride lately. Shares climbed 44% over the past month and a wild 78% over the last week, fueled by a combination of strong earnings, an important manufacturing deal, and the kind of momentum that makes small-cap traders take notice.

Then came Friday's reality check: the company announced it's raising fresh capital, and the stock gave back a chunk of those gains.

The Capital Raise That Cooled the Rally

Intelligent Bio said it will raise $10 million through a private placement, and investors weren't thrilled about the dilution. The deal includes 2.298 million shares plus two series of warrants, K-1 and K-2, each allowing the purchase of up to 2.298 million additional shares. The combined offering price is $4.35 per share, with both warrant series carrying an exercise price of $4.10.

It's a fairly standard structure for micro-cap fundraising, but it's still dilutive, which explains why shares pulled back after the announcement. When you're a small company raising capital at these levels, existing shareholders feel the pinch.

What Sparked the Initial Surge

Before the capital raise threw cold water on the party, Intelligent Bio had genuine reasons for optimism. Earlier in the week, the company announced a strategic manufacturing partnership with Syrma Johari MedTech Ltd. The collaboration is designed to support and scale production of the Intelligent Fingerprinting Drug Screening Reader, the company's flagship product.

Management expects this partnership to drive long-term margin improvement and deliver meaningful operational and financial benefits. For a micro-cap trying to scale a novel technology, securing a manufacturing partner is a legitimately important milestone.

The Numbers Look Good

The company's recent earnings also gave investors something to get excited about. For the first quarter of fiscal 2026, Intelligent Bio reported revenue of $1.11 million, up 32% year over year. The growth was driven by accelerating cartridge sales and customer acquisition, which is exactly what you want to see from a company trying to commercialize its technology.

Even more impressive was the margin expansion. Gross margin jumped 690 basis points to 46.6%, reflecting improved operating efficiency and a higher contribution from those higher-margin cartridge sales. When a small company can grow revenue while simultaneously expanding margins, it suggests the business model is starting to work.

Other Recent Developments

Intelligent Bio has been busy on multiple fronts. In December, the company completed a 1-for-10 reverse stock split, a common move for micro-caps looking to maintain exchange compliance or improve their stock price optics.

Back in July, the company finalized cybersecurity testing, including penetration and electromagnetic compatibility testing. It also reaffirmed the reliability and accuracy of its technology through advanced quantification methods such as human eccrine sweat testing. For a medical device company, these technical validations matter for regulatory and commercial credibility.

At the time of publication Friday, Intelligent Bio Solutions shares were down 20.25% to $7.60. The stock's volatile trajectory illustrates the double-edged sword of micro-cap investing: exciting growth prospects can drive big rallies, but capital raises and dilution can quickly reverse momentum.